Between January and August 2019, Russia produced 255.8 bln RUB worth of pharmaceutical drugs (manufacturers’ prices, VAT included), which is in monetary terms (rubles) 20.2% higher than that of the same period in 2018. In physical terms, the dynamics are +4.5%, with the production volume of 2.83 bln units. If calculated in minimum dosage units (MDU), the dynamics are +3.5%, with the production volume of 47 bln MDUs.

Between January and July 2019, Russia imported 37.7 bln RUB worth of veterinary products (free circulation prices, VAT included), which is in monetary terms (rubles) 0.1% lower than that of the same period in 2018. The negative dynamics are only due to the import of feed supplements dropping by 12.4%. However, the import of feed supplements is the leader in the volume of import in monetary terms with 19.2 bln RUB. The dynamics in physical terms (units) are only negative, -2.4%.

Between January and July 2019, Russia imported 69.5 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms (rubles) 26.5% higher than that of the same period in 2018. As earlier, a significant price increase contributed to the high dynamics. In physical terms (tons), the dynamics are +4.5%, with the import volume of 7 thousand tons.

In July 2019, Russia imported 61.5 bln RUB worth of ready-made pharmaceuticals (free circulation prices, VAT included), which is in monetary terms (rubles) +31.5% higher than that of July 2018 and the highest volume since August 2010. Higher dynamics were witnessed in June 2016. However, the dynamics in physical terms are only +7.3%, with the import volume of 183.3 bln units.

It is unlikely that by the end of this year the pharmaceutical wholesale will have seen any significant achievements or failures. As of yet, the market is only developing in terms of public procurement. The public procurement segment has always been a very specific area, with a limited circle of players and its own rules, which are also very vaguely worded. For example, that massive breakdown in trading due to difficulties in setting the initial maximum price of the contract.